Publication date: Aug 01, 2023
A 33-year-old male with severe COVID-19 required prolonged veno-venous extracorporeal membrane oxygenation (ECMO) support. Following decannulation, he developed an Enterococcus faecium empyema. Tube thoracostomy and broad-spectrum antibiotics were initiated, followed by an unsuccessful attempt at pleural irrigation with saline, given the patient had an increased risk of bleeding due to the concomitant requirement for systemic anticoagulation. Subsequently, intrapleural tissue plasminogen activator (tPA) and recombinant human Dornase alfa (DNase) were safely administered with the resolution of empyema. Enterococcus faecium is an uncommon cause of pleural empyema and, to our knowledge, has not previously been reported to be associated with COVID-19 or ECMO.
| Concepts | Keywords |
|---|---|
| Anticoagulation | anticoagulation |
| Enterococcus | covid-19 |
| Old | ecmo |
| Recombinant | enterococcus faecium |
| Thoracostomy | pleural empyema |
| veno-venous ecmo | |
| vv ecmo |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Enterococcus faecium |
| disease | MESH | Empyema |
| disease | MESH | COVID-19 |
| disease | MESH | Acute Respiratory Distress Syndrome |
| disease | MESH | bleeding |
| drug | DRUGBANK | Alteplase |
| drug | DRUGBANK | Dornase alfa |
| disease | MESH | pleural empyema |